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Abstract
Human patients with myoclonic epilepsy with ragged-red fibers (MERRF) suffer from regionalized pathology caused by a
mutation in the mitochondrial DNA (m.8344ARG). In MERRF-syndrome brain and skeletal muscles are predominantly affected,
despite mtDNA being present in any tissue. In the past such tissue-specificity could not be explained by varying mtDNA
mutation loads. In search for a region-specific pathology in human individuals we determined the mtDNA/nDNA ratios along
withthe mutationloads in43differentpost mortem tissuesamplesofa 16-year-oldfemale MERRF patient and infourpreviously
healthy victims of motor vehicle accidents. In brain and muscle we further determined the quantity of mitochondrial proteins
(COXsubunitsIIandIV),transcriptionfactors(NRF1andTFAM),andVDAC1(Porin)asamarkerforthemitochondrialmass.Inthe
patient the mutation loads varied merely between 89–100%. However, mtDNA copy numbers were increased 3–7 fold in
predominantly affected brain areas (e.g. hippocampus, cortex and putamen) and in skeletal muscle. Similar increases were
absent in unaffected tissues (e.g. heart, lung, kidney, liver, and gastrointestinal organs). Such mtDNA copynumber increase was
not paralleled by an augmentation of mitochondrial mass in some investigated tissues, predominantly in the most affected
tissue regions of the brain. We thus conclude that ‘‘futile’’ stimulation of mtDNA replication per se or a secondary failure to
increase the mitochondrial mass may contribute to the regionalized pathology seen in MERRF-syndrome.
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Introduction
Mutations of the mitochondrial DNA (mtDNA) cause a variety of
serious genetic disorders with maternal inheritance [1]. One example
is the MERRF-syndrome (myoclonic epilepsy with ragged-red fibers,
MIM 545000), which is characterized by myoclonic seizures, ataxia,
dementia, muscle weakness and accumulations of structurally
abnormal mitochondria in the skeletal muscle [2]. MERRF-syndrome
is most frequently associated with the m.8344ARG mutation in the
mitochondrial tRNA
Lys gene (MTTK) [3]. The mutation usually
occurs in heteroplasmic state where wildtype and mutant mtDNA
copies coexist. Generally, MERRF patients have a high percentage of
mutant mtDNA (.9 0 % )i nb l o o da n dm u s c l ea n dt h ed e g r e eo f
heteroplasmy (=mutation load) is evenly distributed between different
organs [4–6], which stands in contrast to the MELAS-syndrome
(MIM 540000), where more variation is found [7]. Cultured myotubes
from MERRF patients show a biochemical defect only if their
mutation load surpasses 85% and show a steep decline of COX-
activity and mitochondrial translation rate beyond this threshold [8].
Even though mitochondria are present in every cell, MERRF-
syndrome has a regionalized pathology, predominantly involving the
brain (hippocampus, cerebral cortex and striatum) and the skeletal
muscle, but often sparing the heart and other intestinal organs. In the
past, researchers have tried to explain this phenomenon by differences
of mutation load for the m.8344ARG mutation in the various organs.
However, various studies did not confirm such an association [4–6,9].
Alternatively, it was hypothesized that the affected tissues had lower
threshold levels for clinical manifestation than their unaffected
counterparts. Other explanations were tissue specific mechanisms
for the regulation of energy metabolism, potentially at the level of
mtDNA replication, transcription or translation.
Here we studied the regionalized pathology of MERRF-
syndrome on tissue and molecular level through investigation of
43 post mortem tissue-samples from different regions of a 16-year-old
girl with MERRF-syndrome and of blood DNA samples from her
family (Figure 1A).
Methods
Ethics statement
Written informed consent according to the Declaration of
Helsinki was obtained from the involved persons and guardians.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13513Figure 1. Analysis of the MERRF patient and her family members. (A) Pedigree of the family of the index patient (3_2). The mutation loads
for the m.8344ARG mtDNA mutation, as determined by PyrosequencingH are given below the pedigree symbols. The black symbols depict patients,
who were clinically affected with MERRF-syndrome; however, even family members with 93% mutant mtDNA in blood cells did not report any
MERRF-specific symptoms and their symbols thus remain white. (B) The electron microscopic image of the iliopsoas muscle (12,0006) shows massive
subsarcolemmal accumulations of mitochondria, which represent the contents of a ragged-red fiber. (C) At higher magnification (85,0006) ballooned
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Charite ´. Consent for the animal studies was obtained from the
LaGeSo Berlin (O 0083/08) according to the animal welfare act.
Morphometric analysis
A tissue sample from the patient’s insular cortex (Brodman area
43) including all neuronal layers and the white matter was fixed for
.4 weeksinphosphate-buffered4%formaldehyde,dehydratedand
subsequently embedded in paraffin. Microtome sections of 5 mm
were mounted on glass slides, deparaffinized, stained with anti-
NeuN and subsequently with Cy3-labeled fluorescent secondary
antibodies. The cell nuclei were counterstained with DAPI. An
unbiased counting frame of 186.26139.6 mm
2 was then systemat-
ically moved through the cortical layers of interest and photographs
were taken on the UV and Cy3-channel through a 206 oil
immersion objective (Leica Microsystems, Wetzlar, Germany) with
a SPOT3 cooled CCD camera (Visitron, Puchheim, Germany).
From each cortical layer we analyzed five such frames which thus
represented 130,000 mm
2 of cross-sectional plane per respective
cortical layer. The two images from the DAPI and the Cy3-channel
were superimposed with false colors and on each frame we
separately counted the total number of DAPI positive nuclei versus
those nuclei that co-localized with a NeuN-signal representing
neuronal cells that had been cut in the plane of the nucleus. All 2D-
counts were corrected with the Abercrombie formula [10] taking
into consideration the thickness of the section (5 mm) and the
diameter of the cell nuclei. The Ferret’s diameter of the nuclei was
1465 mm and had been determined in 50 random neuronal nuclei
at their largest optical cross-sectional diameter with a 636 oil
immersion objective. The Abercrombie-corrected cell densities
were then compared to published reference values that had been
obtained by the same staining and 2D-counting method [11,12].
The final results were then depicted as neurons/mm
2 and as glia/
neuron ratio (Figure 2A,B).
PyrosequencingH assay for determination of mutation
load
DNA was isolated from blood cells and from tissues according to
standard procedures using a 96-well tissue DNA extraction kit
(Qiagen, Hilden, Germany). We amplified a 139 bp PCR-product
of the mitochondrial tRNA
Lys gene with the primer pair 59-CCC
TAT AGC ACC CCC TCT AC-39 and 59-Biotin-TGG GCC
ATA CGG TAG TAT TT-39. The PCR product was sequenced
using the automated PSQ
TM HS 96A system with the primer 59-
TAA GTT AAA GAT TAA GAG A-39. To correct for potential
systematic errors of the assay, all data points of the samples were
normalized to a calibration curve, generated with standardized
mixtures of wildtype and mutant mtDNA (R
2=0,9997; Figure
S3).
qPCR for determination of mtDNA copy numbers
The following primers and probes were used for amplification
one gene encoded by the mtDNA and another single copy gene
encoded by the nDNA: MTND1 (=mtDNA copy numbers):
(F) 59-CTA CAA CCC TTC GCT GAC GC-39, (R) 59-ACG
GCT AGG CTA GAG GTG GC-39, (P) FAM-CCA TCA CCC
TCT ACA TCA CCG CCC-X-TAMRA-39 and for MMP1
(=nuclear DNA copy numbers): (F) 59-GCC AGG GTA
CTG CAC TAG CAT G-39, (R) 59-GAG GCC CTA ACA TTC
TCT GCA CT-39, (P) FAM-TGT GCT ACA CGG ATA CCC
CAA GGA CAT C-X-TAMRA-39. The PCR for each sample was
run in triplicate on an ABI PRISM 7700 sequence detection
system (Applied Biosystems) with a hotstart Taq polymerase
(Platinum Taq). A 10 min denaturation step at 94uC was followed
by 45 cycles of denaturation at 94uC for 30 s and annealing/
extension at 67uC for 60 s. The TaqMan readings were analyzed
using the ‘‘Sequence Detector’’ v1.6.3 software (Applied Biosys-
tems). On each 96-well plate we amplified in parallel a standard
dilution series (10
0–10
7 copies/ml) for every gene, which
subsequently enabled us to determine absolute copy numbers
while taking into account the different PCR efficiencies [13]. If the
standard deviation between the reads of a triplicate sample was
above 10% the measurement had to be repeated.
Western blot
Protein was extracted from tissue samples of the patient and the
controls after homogenization in RIPA buffer with a proteinase
inhibitor cocktail (CompleteH, Roche-Diagnostics, Basel, Switzer-
land), 50 mg protein were separated through denaturating SDS-
PAGE with the Laemmli system and blotted on nitrocellulose
membranes by the semidry method (Biometra, Go ¨ttingen,
Germany). The blots were first probed with antibodies against
mitochondria with paracrystalline inclusions can be seen. (D) Ragged-red fibers in the Go ¨mo ¨ri trichrome stain of the iliopsoas muscle that are COX
negative in (E), and show subsarcolemmal accumulations of enzyme activity in the SDH stain (F).
doi:10.1371/journal.pone.0013513.g001
Figure 2. Morphometric analysis of neuronal cell density in the
insular cortex of the index patient. (A) Density of cortical neurons
using Abercrombie correction. The open bar from the patient
represents the neuronal density from 130,000 mm
2 of cross-sectional
plane per cortical layer. (B) Ratio between the numbers of glial versus
neuronal cells. Black bars, control individuals from the literature
(reference provided); open bars, MERRF patient; the whiskers depict
the SEM; n.a., data not available.
doi:10.1371/journal.pone.0013513.g002
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and GAPDH and subsequently with corresponding peroxidase-
labeled secondary antibodies. Bands were visualized by chemilu-
minescence. All antibodies used in this study are described in
Table S2. b-Tubulin and GAPDH bands were used as loading
controls for brain and muscle respectively.
Results
Case history
The girl was the second child of healthy non-consanguineous
German parents. Her older sister is healthy. Pregnancy, birth and
postnatal development were normal. Myoclonic-astatic seizures
started at 4 years of age. Henceforward symptoms progressed to
severe pharmaco-resistant myoclonic epilepsy with series of
bitemporal spike-waves on EEG and several seizures daily,
progressive ataxia, deafness (hearing threshold of 65 dB SPL),
and mental retardation (HAWIK IQ=76 at the age of 9 years).
Serum lactate (4.1 mmol/l, N,2.0) and alanine (0.60 mmol/l,
N,0.48) concentrations were increased and a diagnostic muscle
biopsy at the age of 9 years revealed the presence of ragged-red
and COX-negative fibers (Figure 1B–F). At 14 years of age
echocardiography and ECG were normal and cranial MRI
revealed ex vacuo dilatation of the lateral ventricles and hippocam-
pal sclerosis. Two years later she was found lifeless in bed and
could not be resuscitated. Autopsy at 48 h post mortem, during
which we were allowed to take small specimens (Table S1), did not
discover any cardiac or pulmonary abnormalities, excluded
asphyxia or aspiration, and finally status epilepticus during sleep
was suspected as the cause of her death. As controls we used
specimens of the same tissues from four previously healthy women
(16 to 32 years), who had suffered fatal motor vehicle accidents.
Additionally, we analyzed the segregation of the mutation and its
mutation load in blood samples of different family members
(Figure 1A).
Reduced neuronal density at the insular cerebral cortex
In our MERRF patient we found a reduction of neuronal
density in the cortical layers IV, V, and VI of more than three
times the SEM if compared to normal controls from the literature
[11,12]. The ratio between glial and neural cells (Figure 2B) was
increased in the layers III and V (no reference data were available
for cortical layer IV) suggesting a replacement of neurons by glial
cells. However, the reduction in the number of cortical neurons
was not as obvious as described in a review by Sparaco et al. (1993),
which may be due to the much younger age of our patient in
whom degenerative changes might just have begun [14].
Little variation between mutation loads of different
tissues
The m.8344ARG mutation loads in the blood of family
members and in the tissue biopsy specimens were determined by a
highly accurate PyrosequencingH assay. This real-time sequencing
technology allows quantification of two mitochondrial alleles that
differ at one nucleotide position with down to 1% heteroplasmy
[15,16]. In the blood of the patient we measured a mutation load
of 96%. As the mutation loads in blood cells from the clinically
unaffected relatives ranged from 0–93% (Figure 1A), we assume a
critical threshold level for clinical manifestation in this family
between 93–96% for the m.8344ARG mutation. This result
confirms other studies that found mutation loads .90% in blood
or muscles of MERRF patients with clinical or histochemical
muscle abnormalities [17–19]. In a severely affected nephew of
our patient (individual 4_1, Figure 1A), who had died also from
status epilepticus at the age of 2 years, we even detected a mutation
load of 100% (=homoplasmy) in blood cells. Such a high
mutation load had not been reported before and had originally
been considered incompatible with life because COX-activities
were extremely low in cultured myotubes with homoplasmy for the
mutation [8]. Next, we determined the mutation loads in the 43
tissue samples of the index patient with the same PyrosequencingH
assay. The mutation loads were more or less evenly distributed
between 89–100% (Table S1), without preference for a specific
tissue type. Only liver and pancreas had lower mutation loads of
67 and 73%, respectively. Similar uniform distributions were
described before [4–6], failing to explain the regionalized
pathology of MERRF-syndrome.
mtDNA copy numbers are preferably increased in the
most affected tissues
As cells from different tissues vary considerably in their mtDNA
content, we next investigated whether the remaining wildtype
mtDNA molecules per cell might correlate with the regionalized
symptoms. In order to calculate this figure we determined the
mtDNA copies per cell for all tissues by quantitative real-time
PCR (TaqManH) of the mitochondrial encoded MTND1 gene
(NADH:ubiquinone oxidoreductase, subunit ND1) versus the single
copy nuclear MMP1 gene (Matrix metalloproteinase 1). MtDNA
copy numbers were increased between 3–7 fold in those tissues of
the patient that were predominantly affected by the MERRF-
mutation (hippocampus, cortex, striatum and skeletal muscle), but
not in other tissues such as heart, lung, liver or intestinal organs
(Figure 3A). Using the mtDNA copy numbers and the mutation
load for each tissue we calculated the number of residual wildtype
mtDNA copies per cell. There, the highly affected tissues still had
the highest remaining absolute numbers of wildtype mtDNA
copies per cell (Figures S1 and S2).
Effect of the storage conditions on the ratio between
mtDNA and DNA
As the ratio between mtDNA and nDNA copy numbers could
strongly be influenced by unequal degradation of mitochondrial
versus nuclear DNA during storage of the body in the morgue at
4uC [20], we investigated mice carcasses which had been kept
under various storage conditions. We measured the mtDNA/
nDNA ratios in 7 representative mouse tissues (brain, cerebellum,
heart, kidney, liver, muscle and pancreas) under two storage
conditions. The qPCR experiment was performed in triplicate as
previously described [21]. After atlanto-axial dislocation the
animals were kept at room temperature for 6 h and then organs
were removed and stored for 60 h at 4uC versus immediately at
220uC. With the exception of pancreas (p,0.001) we did not find
significant differences in mtDNA/nDNA ratios (Figure 3B). Only
the nuclear DNA of the pancreas seemed to be more prone to
degradation at 4uC as compared to 220uC. These results
confirmed the constancy of the mtDNA/nDNA ratio over the
selected time period, especially in brain and muscle. Hence we
have reason to assume that the mtDNA/nDNA ratios measured
with the TaqManHassay truly reflect those at the time of death,
with the exception of the pancreas.
Determination of the mitochondrial mass
Further, we investigated whether the elevated mtDNA/nDNA
ratios were solely due to enhanced mtDNA-replication or caused
by a real increase of the number of mitochondrial organelles per
cell (=mitochondrial mass). We thus extracted total protein from
brain specimens and pectoralis muscle of patient and controls and
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antibodies against Porin (VDAC1). This protein being highly
expressed at the outer mitochondrial membrane [22] serves as a
marker for mitochondrial mass [23]. Due to the small volumes of
many biopsy specimens, we were limited in the number of tissues
to be analyzed by this method but we were able to investigate
hippocampus, putamen, and pectoralis muscle, representing
tissues that are affected in MERRF-syndrome, and the occipital
white matter and the pons, representing tissues that remain mostly
unaffected. The mitochondrial mass of the patient’s hippocampus
and putamen was within the range of controls (Figure 4B). In
contrast, a more than two-fold increase was found in pons, white
matter, and skeletal muscle. Thus, we did not find a general
correlation between increased mtDNA abundance and increased
mitochondrial mass. On the contrary, in the investigated brain
regions we either found an increase in mtDNA copy numbers or
in mitochondrial mass. Only in skeletal muscle we found a parallel
increase of both parameters.
Next we examined, whether high mtDNA copy numbers might
be secondary to a stimulation of mtDNA transcription via up-
regulation of mitochondrial transcription factors. Semi-quantita-
tive Western blot analysis of the transcription factors NRF1
(nuclear respiratory factor 1) acting on nuclear genes that encode
respiratory chain subunits, and TFAM (mitochondrial transcrip-
tion factor A) stimulating mtDNA transcription, revealed no
correlation of their amounts with the mtDNA copy number of the
analyzed brain regions (Figure 4C,D). The TFAM levels in the
organ with one of the largest increase in mtDNA copy numbers
Figure 3. Determination of the absolute mtDNA copy numbers per cell in different tissues by quantitative real-time PCR (TaqManH).
(A) The ratio between mtDNA and nDNA copy numbers. The grey bars indicate mean values of the four controls (each sample analyzed in
quadruplicate) and the black diamonds indicate mean values of the measurements from the patient’s tissues. The whiskers represent the standard
deviation; the tissues encircled by boxes were further investigated on the protein level. (B) Influence of the storage conditions on the mtDNA/nDNA
ratios. With the exception of the pancreas, no significant differences on the 1% confidence level were found between the two storage conditions with
regard to the mtDNA/nDNA ratios. n.s. not significant; * p,0.001. In pancreas the nuclear DNA degraded faster than the mtDNA at 4uC.
doi:10.1371/journal.pone.0013513.g003
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the patient’s pectoralis muscle where a fourfold up-regulation of
TFAM was paralleled by a similar increase of mitochondrial mass.
Finally we investigated the balance of abundance between
proteins encoded by the mitochondrial versus the nuclear genome.
For that we determined the integrated band densities on Western
blots that had been co-stained with antibodies against COX
subunit II (26 kDa, mtDNA encoded) and COX subunit IV
(18 kDa, nDNA encoded). Here again, the protein expression was
balanced in all investigated brain regions irrespective of their
mtDNA copy number and mitochondrial mass (Figure 1E). Only
in muscle we found this relation considerably and unexpectedly
skewed more than fourfold towards the mtDNA encoded subunit
Cox II (Figure 4E,F). As mitochondrial mass was increased in a
similar range in muscle (3.5 fold) we hypothesize that synthesis and
import of nuclear encoded mitochondrial proteins might not have
been increased strictly in parallel. The subsequent deposition of
overproduced subunits might have led to the appearance of
paracrystalline inclusions in many of the muscle mitochondria as
seen on Figure 1C. As alternative explanation, the intense Cox II
band might not represent intact subunits but misfolded or partially
miscomposed polypeptide chains caused by a lack of tRNA
Lys
which recognizes 4 of 227 codons in Cox II mRNA.
Discussion
It is generally agreed that ATP deficiency and increased
production of reactive oxygen species (ROS) are crucial factors in
the pathophysiology of mitochondrial disorders due to mtDNA
mutations and deletions [1,24]. ROS are generated through
electron leaks in a dysfunctional respiratory chain, however, their
harmful effects on the mtDNA may be mitigated, at least partially,
by compensatory up-regulation of mtDNA copy numbers and
mitochondrial mass. H2O2 in the low mM range increases mtDNA
copy numbers and mitochondrial mass in cultures of yeast as well
as human cells and cybrids harboring the 4,977 bp deletion
[25,26]. Moreno-Loshuertos et al. (2006) even went as far as to
propose that respiration deficient phenotypes caused by certain
Figure 4. Determination of protein abundance for structural mitochondrial proteins and for transcription factors. (A) Western blot of
tissue samples from the putamen of three controls (C2-4) and the patient (individual 3_2 on Figure 1A). Protein abundance was determined semi-
quantitatively through densitometry. b-Tubulin was used as loading control. (B) Results of the semi-quantitative analysis of the mitochondrial mass as
represented by anti-Porin (VDAC1) immune reactivity. The whiskers represent the absolute (100%) range of all three control measurements. The result
of the patient is represented as a black dot. Figures (C) and (D) represent the quantification of the transcription factors NRF1 and TFAM. (E) Relative
abundance of the nuclear encoded subunit of cytochrome C oxidase (COIV) versus an mtDNA-encoded subunit (COII) of the same complex. The
immune staining with both antibodies was done on the identical blot which secured the comparability. (F) Only in muscle the mtDNA-encoded COII
subunit was much higher expressed (4.56) than its nDNA encoded counterpart. Note: Due to the lack of sufficient autopsy material the loading of
each lane could not be adjusted. However, these Western blots are only intended to illustrate an equal abundance of proteins encoded by the
nuclear (COIV) versus the mtDNA (COII) and the absence of this balance in the muscle of the MERRF patient.
doi:10.1371/journal.pone.0013513.g004
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compensated via ROS-mediated increase of mtDNA copy
numbers [27], a view that did not remain unchallenged [28].
Hori et al. (2009) proposed an attractive link between increased
ROS production and enhanced mtDNA replication via increased
nicking by Ntg1 of oxidized single-stranded mtDNA at the origin
of replication and thus initiating rolling cycle replication of yeast
mtDNA [29]. Whether a homologous mechanism applies for
mammalian mtDNA is currently unknown.
Here we demonstrate for the first time that the augmentation of
mtDNA copy numbers in a MERRF patient is a tissue-specific
phenomenon, which might help to explain the preponderance of
certain organs for disease-specific symptoms. However, the
question remains whether the up-regulation of mtDNA copy
numbers is a compensatory, albeit insufficient step caused by
increased ROS production in metabolically ‘‘demanding’’ tissuesor
whether such an up-regulation, especially if not followed by a
subsequent increase in mitochondrial mass, may be harmful per se as
it may exhaust the resources of the mitochondria. As TFAM is
known to have an influence mtDNA copy numbers [24], we
investigated its expression in predominantly affected and unaffected
tissues. In brain we found an especially low expression for putamen
and hippocampus which did not up-regulate their mitochondrial
mass despite high mtDNA copy numbers (Figure 5). This stood in
contrast to white matter and pons that augmented their
mitochondrial mass. In the muscle of the patient, elevated
mitochondrial mass and TFAM abundance went strictly parallel
demonstrating that the mechanism(s) to increase mitochondrial
mass are at least partially independent of TFAM. This has already
been shown in muscle specific Tfam-knockout mice that were able
to up-regulate mitochondrial mass in the absence of Tfam [30].
Unfortunately, lack of sufficient autopsy material prohibited the
investigation of other tissues. We are aware that the data being
obtained from a single individual have to be confirmed by further
investigations of MERRF patients and preferably also in
individuals with other mtDNA mutations, especially the MELAS
(m.3243ARG) mutation, to explore whether a tissue-specific
increase in mtDNA copy numbers is a MERRF-specific
phenomenon or whether it may be generalized for other
mitochondrial disorders as well.
Supporting Information
Figure S1 Increase [in %] of the mtDNA copy numbers in the
patient in relation to the mean of the four controls. The tissues
mainly affected by the MERRF-syndrome cluster on the left side
of the chart.
Found at: doi:10.1371/journal.pone.0013513.s001 (0.65 MB TIF)
Figure S2 Absolute numbers of residual wildtype mtDNA
molecules per cell in the patient tissues (magenta dots). The blue
bars depict the mean and the whiskers the standard deviation of
the mtDNA copy numbers in the four controls.
Found at: doi:10.1371/journal.pone.0013513.s002 (1.01 MB TIF)
Figure S3 Calibration curve for the Pyrosequencing assay.
Measurements from the assay were plotted against the expected
degrees of heteroplasmy from known mixtures between plasmid
preparations containing the wildtype and mutant DNA sequence.
All measurements were performed in triplicate and the standard
deviation is indicated by whiskers. Due to the high precision of the
method with small standard deviations, not all the whiskers can be
seen. The regression line forms a smooth curve with the above
Figure 5. Relation between mtDNA copy numbers and mitochondrial mass. The figure depicts an X-Y plot of mtDNA copy numbers versus
mitochondrial mass in five representative tissues. Mitochondrial mass is represented by the reference-corrected density of Western blot bands from
the outer mitochondrial membrane protein porin. The red line depicts the average of the mitochondrial mass, which was calculated as the geometric
means from all control individuals. Circles represent clinically affected tissues and triangles unaffected tissues. Closed symbols represent the control
individuals and open symbols the patient. Muscle, which was clinically only mildly affected, is represented by the diamond shaped symbol.
doi:10.1371/journal.pone.0013513.g005
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13513mentioned equation and a very good approximation of the
measurements. All raw measurements of the samples were
normalized to the regression curve.
Found at: doi:10.1371/journal.pone.0013513.s003 (0.33 MB TIF)
Table S1 Mutation loads (=degrees of heteroplasmy in [%]) of
all the organs as measured by the Pyrosequencing assay. The
numbers indicate the average of three measurements 6 standard
deviation.
Found at: doi:10.1371/journal.pone.0013513.s004 (0.95 MB TIF)
Table S2 Primary antibodies and their dilutions used for
Western blot and immunohistochemistry.
Found at: doi:10.1371/journal.pone.0013513.s005 (0.11 MB TIF)
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